Karyopharm to Present at B. Riley Securities Oncology Investor Conference

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that President and CEO Richard Paulson will present virtually at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 9:30 a.m. ET. Investors can access a live webcast of the presentation under the 'Events & Presentations' section of Karyopharm's website. The company specializes in innovative cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which has received multiple regulatory approvals. For more details, visit www.karyopharm.com.

NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 28 at 9:30 a.m. ET.

A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event. 

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation.  Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications, and has received regulatory approvals in a growing number of ex-U.S. territories and countries, including Europe (as NEXPOVIO®), the United Kingdom and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-b-riley-securities-oncology-investor-conference-301465450.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What is the date and time of Karyopharm's presentation at the B. Riley Securities Oncology Investor Conference?

Karyopharm's presentation is scheduled for January 28, 2022, at 9:30 a.m. ET.

Who will present for Karyopharm Therapeutics at the conference?

Richard Paulson, President and CEO of Karyopharm, will be presenting at the conference.

Where can I watch the Karyopharm presentation live?

The live presentation can be accessed on Karyopharm's website in the 'Events & Presentations' section.

What is Karyopharm Therapeutics known for?

Karyopharm is known for pioneering novel cancer therapies, particularly its lead compound XPOVIO® (selinexor).

Is the Karyopharm presentation available for replay?

Yes, the presentation will be available for replay for 30 days after the event.